Sir, Linezolid, an oxazolidinone with broad-spectrum activity against Gram-positive bacteria, is an effective antibiotic against Staphylococcus aureus and MRSA infection. However, there is limited information on its use in breastfeeding women and the potential for subsequent absorption in the nursing infant, which makes provision of advice to the mother difficult and may lead to parental anxiety. To date, there has been only one case report 1 and one study, 2 both showing linezolid to be detectable in expressed breast milk, but no report of drug levels in nursing infants. The product literature states that linezolid is excreted in the milk of lactating rodents at a similar concentration to that of maternal plasma. 3 Since the absolute bioavailability of linezolid approaches 100%, 3 if the amount of linezolid excreted in human breast milk is sufficiently high, it may be theoretically possible for the drug to be found in clinically significant amounts in the systemic circulation of the infant.
We present a case report of a nursing mother treated with linezolid for S. aureus bacteraemia. Linezolid was prescribed because of a proven b-lactam allergy and no intravenous access. We measured linezolid levels in expressed breast milk provided by the patient and in one serum sample from the exclusively breastfed newborn infant.
Expressed breast milk was collected at various times over a 24 h period by the patient. Collection commenced 45 h after treatment with 600 mg of oral linezolid every 12 h was started. The infant required therapeutic drug monitoring for another antibiotic and the residual serum from this sample was used to measure linezolid levels. Linezolid levels were measured in all samples using HPLC by the Antimicrobial Reference Laboratory in Southmead Hospital, Bristol, UK, using a validated method. 4 The levels obtained for breast milk ranged from 3.5 to 12.2 mg/L with an average level of 8.1 mg/L. Serum measurement of linezolid in the newborn infant was ,0.2 mg/L. A breast milk sample obtained 1 h after the infant's serum sample and 4 h after linezolid administration measured 8.9 mg/L ( Figure 1 ).
The recommended treatment dose of linezolid for neonates is 10 mg/kg every 8-12 h. Assuming breast milk intake of 750 mL per day, 5 based on our findings the average daily exposure of the nursing infant to linezolid was estimated to be 6 mg, which is ,9% of the daily treatment dose in an average 3.5 kg neonate. This is consistent with the currently available literature suggesting that the nursing infant of a breastfeeding mother on standard-dose linezolid therapy would receive around 3%-6% of the normal infant treatment dose of linezolid.
1 Interestingly, the infant linezolid serum concentration measured 44 h after commencement of maternal oral linezolid administration was below the limit of HPLC detection despite the infant being fed exclusively on breast milk. Unfortunately, it was not possible to ascertain the timing of the serum sample in relation to when the infant was last fed, but the breast milk sample collected closest in time to the serum sampling had a concentration of 8.9 mg/L.
To our knowledge, this is the first report describing the measurement of linezolid in both the breast milk of the mother and in the serum of the nursing infant. We conclude that, both from our results and a theoretical consideration, the risk of systemic exposure of the infant to linezolid during breastfeeding by mothers receiving the drug is low. However, until further data are available to confirm the safety of incidental exposure of the infant to linezolid in breast milk, it would be prudent to continue to monitor for any side effects possibly relating to linezolid exposure, such as diarrhoea and bone marrow suppression. 
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Here we describe the case of a man in his mid-fifties affected by XDR P. aeruginosa osteomyelitis successfully treated with ceftolozane/tazobactam. The patient came to our observation because of recurrence of a bone (left femur) infection. The first osteomyelitis episode occurred after a traumatic fracture and was successfully treated with a 12 week course of trimethoprim/sulfamethoxazole and minocycline. Three months later, the infection recurred. Culture of a deep bone fragment and microbiological examination showed P. aeruginosa susceptible only to colistin with an MIC of 1 mg/L and high MICs of meropenem (64 mg/L) and fosfomycin (32 mg/L). Therefore, the patient was admitted and started therapy with colistin at standard dosage (9 million units as leading dose and 4.5 million units q12h as maintenance dosage) plus rifampicin (300 mg q12h).
Upon admission, serum C-reactive protein (CRP) was 2.49 mg/dL. After 18 days of therapy, the measured glomerular filtration rate (mGFR) showed a decreasing trend and a urine test revealed tubulopathy. Thus, the dose of colistin was progressively reduced and was withdrawn (together with rifampicin) after 26 days when mGFR decreased to 33.1 mL/min; at this time CRP was 0.55 mg/dL.
On day 27, authorized off-label therapy with ceftolozane/tazobactam (not included in the antimicrobial susceptibility testing) was started at 500 mg/250 mg q8h (the dose was halved because of the reduced mGFR) and, after 14 days, when mGFR exceeded 50 mL/min, it was administered at standard dosage. CRP was ,0.33 mg/dL 5 days after this new treatment. We continued ceftolozane/tazobactam to complete an 8 week course. At the end of therapy, CRP was negative and we referred the patient to the orthopaedic centre for the planned surgical revision. At the last follow-up visit (3 months after surgery) the patient was infectionfree.
To our knowledge, this is the first report of the clinical success of ceftolozane/tazobactam used as monotherapy against an XDR P. aeruginosa strain as the causative agent of a monomicrobial osteomyelitis. Notably, ceftolozane/tazobactam plus vancomycin was very recently reported to be effective against MDR P. aeruginosa and diphtheroids in polymicrobial osteomyelitis. 5 There are no data about bone penetration of ceftolozane/tazobactam; however, like other b-lactams, parenteral administration of the drug should guarantee levels exceeding the MIC for
